Study of Efficacy, Safety, and Tolerability of LYS006, in Patients With Mild to Moderate Ulcerative Colitis

NCT04074590 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

23

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision due to strategic considerations

Conditions

Colitis, Ulcerative

Interventions

DRUG: LYS006
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals